CTRI/2011/08/001939Not Applicable2 期
ALERTS (AngeLmed for Early Recognition and Treatment of STEMI) Study - ALERTS
Angel Medical Systems Inc0 个研究点目标入组 1,020 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- Not Applicable
- 发起方
- 入组人数
- 1,020
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion criteria
- •All of the following criteria must be present:
- •1.Subject has at least one of the following conditions:
- •a) Diabetes (Type I or Type II)
- •b) Compromised renal function (Cr 1.2 mg/dl or creatinine clearance less than 50)
- •c) TIMI Risk Score 3
- •2.Presents (within past 6 months) with a high-risk acute coronary syndrome (e.g., Unstable Angina, STEMI or NSTEMI) or has undergone or is scheduled for CABG within 6 months of implantation.
- •3.Has already undergone coronary angiography and revascularization, unless the physician determines it is appropriate to implant before or during the planned procedure.
- •4. Lives in a geographic area in close proximity (within 60 minutes by EMS) to any hospital that can treat AMI.
- •5.Subjects (men or women) at least 21 years of age. Women of childbearing age must have a negative pregnancy test or confirmation of one of the following:
- •a) Post-menopause or amenorrheic during the past year
- •b) Surgical sterilization
- •c) Use of effective contraceptive method
排除标准
- •1.In the investigator?s opinion, subject lacks ability to respond appropriately to alarms, e.g., illiteracy, poor memory or cognitive function, dementia or other condition affecting memory function, etc.
- •2.There is known compromised tissue at the site of lead implantation in the apex of the right ventricle, e.g., prior infarct affecting the RV apex location.
- •3.A permanent pacemaker or ICD is already in place or the patient is indicated for ICD or pacemaker implantation based on the guidelines published by the American College of Cardiology as Class I and IIa recommendations. Class IIb recommendations are at the investigator?s discretion.
- •4.Subject cannot feel the IMD vibration when placed on top of the skin on the left pectoral side of the chest.
- •5.Subject has recurrent or persistent atrial fibrillation.
- •6.Subject has recurrent or persistent non-sinus cardiac rhythm, second or third degree atrioventricular blocks, QRS duration greater than 120 ms, Benign Early Repolarization (BER), or Brugada Syndrome.
- •7.Subject has left ventricular hypertrophy evidenced by EKG criteria.
- •8.Subject has any condition preventing the subcutaneous implantation of the Guardian System in a left pectoral pouch, such as: superior vena cava thrombosis, subcutaneous tissue deemed inappropriate for the procedure or prior central venous access via portacath, Hickman, Groshong, or similar placed in a left pectoral location or left side PICC line.
- •9.Subject has extremely heavy alcohol consumption (participates in binge drinking that leads to alcohol intoxication) or has history of alcohol or illicit drug abuse within past 5 years.
- •10.There is evidence of unresolved infection (fever 38o C and/or leukocytosis 15,000).
- •11.Subject has history of bleeding disorders or severe coagulopathy (platelets 100,000 plts/ml; APTT or PT 1.3 x reference range).
- •12.Subject has had a hemorrhagic stroke or transient ischemic attack (TIA) in the past 6 months.
- •13.Subject has other severe diseases, such as cancer or refractory congestive heart failure, associated with limitation of life expectancy (less than 1 year), which may lead to inadequate compliance to the protocol or confusing data interpretation.
- •14.Subject has clinical conditions such as heart diseases, difficult-to-control blood pressure, difficult-to-control insulin-dependent diabetes or serious prior infections attributed to the diabetes, or others that, at the investigator?s discretion, could seriously affect the subject?s current clinical condition during study procedures.
- •15.Subject has previous participation in the DETECT Study, current participation or previous participation in another drug or device study in the past 30 days that conflicts with this study as determined by the study sponsor.
- •16.Subject has experienced gastro-intestinal hemorrhage in the past 6 months.
- •17.Subject has any situation in which the use of aspirin is contraindicated for at least 6 months.
- •18 Subject has epilepsy.
- •19.Subject has known severe allergies, e.g., peanut, bee sting, etc
研究者
相似试验
招募中
不适用
Early diagnosis and early intervention by alendronate of glucocorticoid-induced osteoporosis in patients who are initially treated with glucocorticoidConnective tissue diseasesJPRN-UMIN000002457niversity of Occupational and Environmental Health, Japan120
已完成
不适用
The EARLY study: Early detection of acute and early-onset cARdiovascuLar toxicitY in children with cancer using a multiparametric approach.10082206cardiomyopathyheart failureNL-OMON49327Prinses Máxima Centrum voor Kinderoncologie100
进行中（未招募）
不适用
Impact of pre-alerts on patients, ambulance service and emergency department staffTrauma and emergency careISRCTN12652860niversity of Sheffield88
已完成
不适用
Early recognition and preventive care for persons being at risk for type 2 diabetes in community pharmacies in Bavaria, GermanyE11Type 2 diabetes mellitusDRKS00006585WIPIG - Wissenschaftliches Institut für Prävention im Gesundheitswesen der Bayerischen Landesapothekerkammer1,140
尚未招募
不适用
Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA StudyThrombotic MicroangiopathiesNCT05996679Fondazione Policlinico Universitario Agostino Gemelli IRCCS29